Back to Headlines
Health
Jun 14, 2026
Analyzed by GPT OSS 120B

UK Approves Wegovy Oral Pill, Expanding Obesity Treatment Options

AI Summary
The UK medicines regulator (MHRA) has approved the first oral Wegovy tablet, making Britain the third country to authorize a GLP‑1 weight‑loss pill. The move could broaden access for millions of patients who currently rely on injectable formulations.

Patients in the UK will soon be able to purchase Wegovy’s oral semaglutide tablet after the Medicines and Healthcare products Regulatory Agency (MHRA) granted its first‑ever approval for a GLP‑1 weight‑loss pill, making the country the third globally to authorize the formulation.

The MHRA Grants First UK Approval for Wegovy Oral Tablet

  • Approval announced 13 June 2026 by the UK medicines regulator.
  • Marks the first GLP‑1 receptor agonist tablet for obesity approved in Europe.
  • Executive vice‑president Emil Kongshøj Larsen of Novo Nordisk hailed it as a “landmark approval”.

Clinical Efficacy and Pricing Landscape

  • Tablet contains semaglutide, approved for adults with BMI ≥30 or BMI 27‑30 with a weight‑related condition.
  • Phase III trials showed a 14‑17% body‑weight reduction after 64 weeks at the highest dose.
  • Current private cost of Wegovy injections ranges from £90‑£300 per month; pill pricing not yet set.
  • Patients will start at 1.5 mg and titrate up to 25 mg, with a month at each level.

Implications for UK Obesity Care and Market Demand

  • Oral formulation expected to increase uptake among those reluctant to inject.
  • Industry analysts predict demand could rival the estimated 2.5 million current injection users.
  • Without NICE endorsement, the pill will remain a private‑prescription product, limiting NHS access.
  • Health leaders stress the drug is not a “magic solution” and must be paired with nutrition, activity, and behavioural support.

Future Outlook: NHS Adoption and Global Competition

  • Approval by NICE will determine whether the pill becomes part of publicly funded care.
  • Success could pressure other European regulators to follow the UK’s lead.
  • Potential price competition with injectable Wegovy may drive overall treatment costs down.
  • Continued monitoring through the UK “yellow card” safety scheme will inform long‑term safety profiles.